Skip to main content

Table 2 Asexual and gametocyte prevalence during follow up

From: Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

 

AL only

AL + primaquine day 1

AL + primaquine day 3

P-value

P-value

 

% (n/N)

% (n/N)

% (n/N)

(AL only vs AL + primaquine day 1)

(AL only vs AL + primaquine day 3)

Asexual parasite prevalence by microscopy

 Day 2

15.1 (5/33)

24.3 (9/37)

13.5 (5/37)

0.338

0.845

 Day 3

0

0

0

 

AL only

AL + primaquine day 1

AL + primaquine day 3

  

Gametocyte prevalence by QT-NASBA

 Day 1

90 (27/30)

82.8 (29/35)

96.8 (30/31)

0.474

0.437

 Day 4

26.7 (8/30)

11.4 (4/35)

25.8 (8/31)

0.364

0.382

 Day 8

13.3 (4/30)

0.0 (0/35)

6.4 (2/31)

0.306

 Day 11

3.3 (1/30)

0.0 (0/35)

0.0 (0/31)

 Mean AUC (95% CI) of gametocyte density versus time*

0.523 (0.467 – 0.579)

0.530 (0.475 – 0.584)

0.508 (0.450 – 0.563)

0.5319

  1. AL artemether–lumefantrine, AUC area under the curve; CI confidence interval
  2. *P-value across the three treatment arms